MannKind Corporation Share Price & Technical Analysis
MNKD · $3.38 (+2.11%)
Healthcare / Biotechnology
$3.38
+2.11%
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve …
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
21% return in May, 6% avg return in past 3 year May month.
-30% return in 2026, 1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 2% | -43% | -22% | 12% | 21% | – | – | – | – | – | – | – | -30% |
| 25 | -11% | -5% | -6% | 0% | -16% | -10% | 3% | 21% | -11% | 4% | -5% | 8% | -29% |
| 24 | -11% | 21% | 7% | -9% | 12% | 11% | 12% | 9% | 2% | 13% | -6% | -6% | 54% |
| 23 | 4% | -2% | -23% | -7% | 21% | -11% | 15% | 2% | -11% | 5% | -14% | 0% | -21% |
| 22 | -14% | -32% | 42% | -16% | 31% | -10% | -8% | 6% | -16% | 6% | 38% | 13% | 41% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Strong
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.02B
P/E ratio
—
52W high
$6.51
52W low
$2.23
Volume
46,04,149
Beta
1.04
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is MannKind Corporation share price today?
- MannKind Corporation (MNKD) last traded around $3.38 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MNKD have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MNKD. Download the app for real-time alerts.
- How can I analyze MannKind Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.